03.01.2020, 21:58
Incyte Corporation - Healthcare | Biotechnology | USA
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
Shares of Incyte Corporation INCY declined 10% after it announced disappointing results from a late-stage study on pipeline candidate itacitinib, (INCB039110) a novel and selective JAK1 inhibitor.
The phase III randomized, double-blind, placebo-controlled GRAVITAS-301 study was evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve (first-line) acute graft-versus-host disease (GVHD).
The primary endpoint was overall response rate (ORR) at day 28, defined as the proportion of subjects demonstrating a complete response, very good partial response, or partial response. The key secondary endpoint is non-relapse mortality (NRM) at month 6, defined as the proportion of subjects who died due to causes other than malignancy relapse.
...
https://finance.yahoo.com/news/incytes-i...03213.html
![[Bild: INCYc1dl1455.png]](https://finviz.com/publish/010320/INCYc1dl1455.png)
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
Shares of Incyte Corporation INCY declined 10% after it announced disappointing results from a late-stage study on pipeline candidate itacitinib, (INCB039110) a novel and selective JAK1 inhibitor.
The phase III randomized, double-blind, placebo-controlled GRAVITAS-301 study was evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve (first-line) acute graft-versus-host disease (GVHD).
The primary endpoint was overall response rate (ORR) at day 28, defined as the proportion of subjects demonstrating a complete response, very good partial response, or partial response. The key secondary endpoint is non-relapse mortality (NRM) at month 6, defined as the proportion of subjects who died due to causes other than malignancy relapse.
...
https://finance.yahoo.com/news/incytes-i...03213.html